<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="927">
  <stage>Registered</stage>
  <submitdate>6/12/2005</submitdate>
  <approvaldate>7/12/2005</approvaldate>
  <actrnumber>ACTRN12605000780651</actrnumber>
  <trial_identification>
    <studytitle>Hypertonic saline during hospitalisation in Cystic Fibrosis study</studytitle>
    <scientifictitle>Phase 3, placebo-controlled, parallel-group, randomised trial of the effect of nebulised hypertonic saline on the length of stay of people hospitalised with acute exacerbations of Cystic Fibrosis lung disease.</scientifictitle>
    <utrn />
    <trialacronym>HSHS Trial</trialacronym>
    <secondaryid>X05-0075</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>7% hypertonic saline with 0.25mg/mL quinine sulphate.  The allocated trial solution is inhaled three times per day for the duration of a hospital admission.</interventions>
    <comparator>0.12% saline with 0.25mg/mL quinine sulphate.  The allocated trial solution is inhaled three times per day for the duration of a hospital admission.</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Duration of the length of stay in hospital</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Lung function (FEV1, FVC, FEF2575).</outcome>
      <timepoint>Daily.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Oxygenation</outcome>
      <timepoint>Daily.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Symptom scores</outcome>
      <timepoint>Daily.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life </outcome>
      <timepoint>At admission, day 7, and discharge. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Exercise tolerance</outcome>
      <timepoint>At admission and day 7. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability of and adherence to the trial solutions throughout the admission. </outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quantitative microbiology of sputum</outcome>
      <timepoint>At admission, day 7 and discharge.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to relapse.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Cystic fibrosis</inclusivecriteria>
    <inclusiveminage>17</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>B. cepacia, major haemoptysis in the last year, ITP, allergy to quinine sulphate, investigational drugs within last 30 days, previous lung transplant, pregnant or breastfeeding, thrombocytopaenia.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Computerised, stratified randomisation performed by the trial pharmacist who is independent of all other activity in the trial.</concealment>
    <sequence>computer-generated, stratified, random allocation using a minimisation algorithm</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>10/12/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>142</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Sydney South West Area Health Service</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>US CF Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Service Ethics Review Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mr Mark Elkins</name>
      <address>Department of Respiratory Medicine
Royal Prince Alfred Hospital
Level 11
E Block
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95158712</phone>
      <fax>+61 2 95158196</fax>
      <email>elkinsm@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Newton-John</name>
      <address>PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156578</phone>
      <fax>+61 2 95505865</fax>
      <email>sarahnj@woolock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>